Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Tuesday, December 31, 2024.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q4 FY2024 (2024-12-31): -191.67%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-271.10%
RETURN ON EQUITY (ROE) AVG 3Y
-323.52%
RETURN ON EQUITY (ROE) AVG 5Y
-123.76%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Gossamer Bio, Inc.
Market Cap
$65.87M
Return on Equity (ROE)
N/A
TTM Avg
-271.10%
3Y Avg
-323.52%
5Y Avg
-123.76%
Market Cap
$65.86M
Return on Equity (ROE)
-122.71%
TTM Avg
-558.46%
3Y Avg
-307.41%
5Y Avg
-314.14%
Market Cap
$65.85M
Return on Equity (ROE)
-35.13%
TTM Avg
-26.80%
3Y Avg
-19.63%
5Y Avg
-14.70%
Market Cap
$67.52M
Return on Equity (ROE)
-38.55%
TTM Avg
-81.03%
3Y Avg
-175.38%
5Y Avg
-133.71%
Market Cap
$64.18M
Return on Equity (ROE)
N/A
TTM Avg
140.07%
3Y Avg
68.30%
5Y Avg
45.41%
Market Cap
$63.78M
Return on Equity (ROE)
-62.81%
TTM Avg
-75.79%
3Y Avg
-56.25%
5Y Avg
-48.09%
Market Cap
$68.10M
Return on Equity (ROE)
68.12%
TTM Avg
-94.32%
3Y Avg
-166.28%
5Y Avg
-128.51%
Market Cap
$63.02M
Return on Equity (ROE)
-8.80%
TTM Avg
-13.04%
3Y Avg
-7.69%
5Y Avg
-7.21%
Market Cap
$68.90M
Return on Equity (ROE)
16.70%
TTM Avg
-67.07%
3Y Avg
-43.48%
5Y Avg
-55.81%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | $65.87M | N/A | -271.10% | -323.52% | -123.76% |
| Cingulate Inc. (CING)vs › | $65.86M | -122.71% | -558.46% | -307.41% | -314.14% |
| XBiotech Inc. (XBIT)vs › | $65.85M | -35.13% | -26.80% | -19.63% | -14.70% |
| iBio, Inc. (IBIO)vs › | $67.52M | -38.55% | -81.03% | -175.38% | -133.71% |
| Alps Group Inc (ALPS)vs › | $64.18M | N/A | 140.07% | 68.30% | 45.41% |
| Pliant Therapeutics, Inc. (PLRX)vs › | $63.78M | -62.81% | -75.79% | -56.25% | -48.09% |
| Fortress Biotech, Inc. (FBIO)vs › | $68.10M | 68.12% | -94.32% | -166.28% | -128.51% |
| InterCure Ltd. (INCR)vs › | $63.02M | -8.80% | -13.04% | -7.69% | -7.21% |
| Spero Therapeutics, Inc. (SPRO)vs › | $68.90M | 16.70% | -67.07% | -43.48% | -55.81% |
| Heron Therapeutics, Inc. (HRTX)vs › | $62.78M | -492.89% | -50.27% | -279.07% | -249.48% |
ROE
N/A
ROA
-162.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2024-12-31 | -191.67% |
| 2024-09-30 | -132.35% |
| 2024-06-30 | -99.17% |
| 2024-03-31 | -645.83% |
| 2023-12-31 | -286.47% |
| 2023-09-30 | -179.16% |
| 2022-09-30 | -407.98% |
| 2022-03-31 | -776.38% |
| 2021-12-31 | -192.65% |
| 2021-09-30 | -142.70% |
| 2021-06-30 | -108.70% |
| 2021-03-31 | -90.75% |
| 2020-12-31 | -75.89% |
| 2020-09-30 | -62.74% |
| 2020-06-30 | -53.33% |
| 2020-03-31 | -65.84% |
| 2019-12-31 | -51.15% |
| 2019-09-30 | -41.22% |
| 2019-03-31 | -31.97% |
| 2018-09-30 | -46.48% |
| 2018-06-30 | -136.38% |
